| Market Capitalization (Millions $) |
0 |
| Shares
Outstanding (Millions) |
0 |
| Employees |
60 |
| Revenues (TTM) (Millions $) |
1 |
| Net Income (TTM) (Millions $) |
-26 |
| Cash Flow (TTM) (Millions $) |
-1 |
| Capital Exp. (TTM) (Millions $) |
0 |
Ovid Therapeutics Inc
Ovid Therapeutics Inc. is a biopharmaceutical company that was founded in 2014 by a team of experienced industry leaders and scientists with the goal of developing treatments for rare neurological diseases. The company is headquartered in New York, NY, and is publicly traded on the NASDAQ under the symbol OVID.
The focus of Ovid Therapeutics is on developing innovative therapeutics for patients with rare neurological disorders, including developmental and epileptic encephalopathies (DEEs) and Angelman syndrome. These disorders are caused by genetic mutations that disrupt proper brain function and often lead to severe intellectual disability and other developmental delays.
Ovid Therapeutics' lead drug candidate, OV101, is a highly selective small molecule that is being developed to treat both Angelman syndrome and Fragile X syndrome. These conditions are caused by a deficiency in the inhibitory neurotransmitter GABA, which OV101 is designed to enhance. OV101 is currently in clinical trials, with Phase 3 studies ongoing in Angelman syndrome and Phase 2 trials in Fragile X syndrome.
In addition to OV101, Ovid Therapeutics is developing several other drug candidates, including OV935, a highly selective dual inhibitor of enzymes that regulate the production of neurotransmitters glutamate and GABA. OV935 is being developed as a potential treatment for both DEEs and epileptic spasms.
Ovid Therapeutics has formed partnerships with several leading academic and research institutions to advance its drug development programs. The company has also received funding from several venture capital firms.
Overall, Ovid Therapeutics is a leading biopharmaceutical company focused on developing innovative therapeutics for patients with rare neurological disorders. With a strong pipeline of drug candidates and a highly experienced management team, Ovid is well-positioned to make a meaningful impact in the lives of patients and families affected by these devastating conditions.
Company Address: 441 Ninth Avenue New York 10001 NY
Company Phone Number: 661-7661 Stock Exchange / Ticker: NASDAQ OVID
|
5.97% 